MileBot recently received a strategic Series B investment of nearly RMB 100 million from CSC Capital.
As founder Dr. Chen Gong said:
We are not building an automated device to replace people. We are creating an intelligent partner that can understand a patient’s intent.
The proceeds from this round will support continued work in three core areas:
Advancing brain-controlled exoskeleton technology
MileBot plans to deepen the integration of exoskeletons with brain–computer interfaces and other emerging technologies, increase R&D investment, and advance clinical validation and product development for exoskeleton solutions designed around clinical needs.
Expanding the product portfolio across care settings
MileBot plans to expand its portfolio across hospitals, communities and homes, including medical rehabilitation robots, community care equipment and consumer exoskeletons for home use. The aim is to support continuity from hospital treatment to community and home settings for more people who need rehabilitation training or walking assistance.
Developing international markets
MileBot plans to develop overseas channels, localized operations and compliance systems as it expands its international presence.